exoIL-12 demonstrates tumor-retained and dose-dependent pharmacology with superior anti-tumor efficacy compared to soluble recombinant IL-12 exoSTING shows unique pharmacodynamic effects and tumor antigen-specific systemic immune responses.
Read More »